Advertisement

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Published:April 18, 2019DOI:https://doi.org/10.1016/j.clgc.2019.04.013

      Abstract

      Background

      Germline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing.

      Materials and Methods

      A 14-item questionnaire was e-mailed to academic oncologists at 43 PCCTC sites to collect information on germline genetic testing patterns, including patients considered, choice of assays, barriers slowing adoption, and actions to overcome barriers.

      Results

      Twenty-six genitourinary oncologists from 19 institutions responded. Less than 40% (10 of 26) reported referring patients to a genetics department, whereas the remainder take personal responsibility for genetic testing and counseling; 16 (62%) consider testing all metastatic PCa patients, whereas 3 (12%) consider testing all patients with high-risk local disease; and 7 (27%) use multigene comprehensive pan-cancer panels, and 14 (54%) use smaller or targeted cancer gene panels. Barriers to widespread use are: (1) delayed or limited access to genetic counseling; (2) no insurance coverage; (3) lack of effective workflows; (4) insufficient educational materials; and (5) time and space constraints in busy clinics. The primary limitation was the <50% (19 of 43) response from PCCTC sites and no coverage of nonacademic cancer treatment facilities.

      Conclusion

      Joint efforts by urologists, oncologists, genetics counselors, insurers, and cancer centers can accelerate implementation of integrated germline genetic services for personalized treatment and clinical trial eligibility for PCa patients.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Giri V.N.
        • Obeid E.
        • Gross L.
        • et al.
        Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation.
        JCO Precis Oncol. 2017; 1: 1-17
        • Pritchard C.C.
        • Mateo J.
        • Walsh M.F.
        • et al.
        Inherited DNA-repair gene mutations in men with metastatic prostate cancer.
        N Engl J Med. 2016; 375: 443-453
        • Mateo J.
        • Carreira S.
        • Sandhu S.
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Cheng H.H.
        • Pritchard C.C.
        • Boyd T.
        • Nelson P.S.
        • Montgomery B.
        Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.
        Eur Urol. 2016; 69: 992-995
        • Pennington K.P.
        • Walsh T.
        • Harrell M.I.
        • et al.
        Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
        Clin Cancer Res. 2014; 20: 764-775
        • Scott C.L.
        • Swisher E.M.
        • Kaufmann S.H.
        Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
        J Clin Oncol. 2015; 33: 1397-1406
        • Le D.T.
        • Durham J.N.
        • Smith K.N.
        • et al.
        Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
        Science. 2017; 357: 409-413
        • Le D.T.
        • Uram J.N.
        • Wang H.
        • et al.
        PD-1 blockade in tumors with mismatch-repair deficiency.
        N Engl J Med. 2015; 372: 2509-2520
        • Boudadi K.
        • Suzman D.L.
        • Anagnostou V.
        • et al.
        Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
        Oncotarget. 2018; 9: 28561-28571
        • De Bono J.S.
        • Goh J.C.H.
        • Ojamaa K.
        • et al.
        KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
        J Clin Oncol. 2018; 36: 5007
        • Carter H.B.
        • Helfand B.
        • Mamawala M.
        • et al.
        Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer.
        Eur Urol. 2019; 75: 743-749
        • Giri V.N.
        • Hegarty S.E.
        • Hyatt C.
        • et al.
        Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing.
        Prostate. 2019; 79: 333-339
        • Nicolosi P.
        • Ledet E.
        • Yang S.
        • et al.
        Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines.
        JAMA Oncol. 2019; 5: 523-528
        • Castro E.
        • Goh C.
        • Leongamornlert D.
        • et al.
        Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer.
        Eur Urol. 2015; 68: 186-193
        • Carlo M.I.
        • Giri V.N.
        • Paller C.J.
        • et al.
        Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: a white paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
        JCO Precis Oncol. 2018; 2018
        • Zon R.T.
        • Goss E.
        • Vogel V.G.
        • et al.
        American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.
        J Clin Oncol. 2009; 27: 986-993
        • Mohler J.L.
        • Armstrong A.J.
        • D’Amico A.V.
        • et al.
        NCCN Clinical Practice Guidelines in Oncology Prostate Cancer, Version 1.2018.
        (Available at:)
        • Parent E.E.
        • Schuster D.M.
        Update on (18)F-fluciclovine PET for prostate cancer imaging.
        J Nucl Med. 2018; 59: 733-739
        • Cantiello F.
        • Crocerossa F.
        • Russo G.I.
        • et al.
        Comparison between 64Cu-PSMA-617 PET/CT and 18F-choline PET/CT imaging in early diagnosis of prostate cancer biochemical recurrence.
        Clin Genitourin Cancer. 2018; 16: 385-391
        • Miyahira A.K.
        • Pienta K.J.
        • Morris M.J.
        • et al.
        Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
        Prostate. 2018; 78: 775-789
        • Giri V.N.
        • Knudsen K.E.
        • Kelly W.K.
        • et al.
        Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017.
        J Clin Oncol. 2018; 36: 414-424
        • National Institutes of Health, National Human Genome Research Project
        The Genetic Information Nondiscrimination Act of 2008.
        (Available at:)
        • National Comprehensive Cancer Network
        Prostate Cancer.
        (Available at:)
        • National Comprehensive Cancer Network
        Genetic/Familial High-Risk Assessment: Breast and Ovarian.
        (Available at:)
        • Riley B.D.
        • Culver J.O.
        • Skrzynia C.
        • et al.
        Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.
        J Genet Couns. 2012; 21: 151-161
        • Robson M.E.
        • Bradbury A.R.
        • Arun B.
        • et al.
        American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
        J Clin Oncol. 2015; 33: 3660-3667
        • Sanda M.G.
        • Cadeddu J.A.
        • Kirkby E.
        • et al.
        Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options.
        J Urol. 2018; 199: 683-690
        • Hoskovec J.M.
        • Bennett R.L.
        • Carey M.E.
        • et al.
        Projecting the supply and demand for certified genetic counselors: a Workforce study.
        J Genet Couns. 2018; 27: 16-20
        • Stoll K.
        • Kubendran S.
        • Cohen S.A.
        The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine.
        Am J Med Genet C Semin Med Genet. 2018; 178: 24-37
        • World Health Organization
        Genomic resource centre. Continuing education for health professionals.
        (Available at:)